Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E- EPS (ttm)-0.62 Insider Own0.80% Shs Outstand280.63M Perf Week2.72%
Market Cap6.35B Forward P/E251.33 EPS next Y0.09 Insider Trans-28.45% Shs Float260.59M Perf Month23.67%
Income-149.00M PEG- EPS next Q-0.01 Inst Own82.90% Short Float6.06% Perf Quarter33.37%
Sales123.80M P/S51.28 EPS this Y41.30% Inst Trans7.72% Short Ratio2.87 Perf Half Y97.73%
Book/sh0.12 P/B188.50 EPS next Y120.50% ROA-36.00% Target Price20.50 Perf Year482.99%
Cash/sh1.14 P/C19.86 EPS next 5Y- ROE160.90% 52W Range3.55 - 23.49 Perf YTD51.71%
Dividend- P/FCF23.02 EPS past 5Y0.90% ROI-43.80% 52W High-3.70% Beta1.87
Dividend %- Quick Ratio2.10 Sales past 5Y-27.50% Gross Margin95.40% 52W Low537.18% ATR0.90
Employees115 Current Ratio2.10 Sales Q/Q528.30% Oper. Margin- RSI (14)67.56 Volatility3.21% 4.78%
OptionableYes Debt/Eq5.97 EPS Q/Q79.00% Profit Margin- Rel Volume0.64 Prev Close23.11
ShortableYes LT Debt/Eq2.55 EarningsFeb 27 AMC Payout- Avg Volume5.51M Price22.62
Recom1.50 SMA2010.53% SMA5024.56% SMA20080.20% Volume3,504,823 Change-2.12%
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Jan-21-14Reiterated Maxim Group Buy $7.50 → $11
Nov-12-13Upgrade Maxim Group Hold → Buy $7.50
May-28-13Downgrade Maxim Group Buy → Hold $35 → $35
Nov-30-12Reiterated Stifel Nicolaus Buy $8 → $9
Apr-20-12Initiated Maxim Group Buy $9
Mar-15-12Resumed Stifel Nicolaus Buy $8
Aug-17-11Initiated Stifel Nicolaus Hold $8
Nov-18-09Downgrade Merriman Buy → Neutral
Jun-17-09Initiated Boenning & Scattergood Neutral
Dec-15-08Reiterated Lazard Capital Buy $7 → $8
Feb-22-17 03:10PM  Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?
08:16AM  Can Penumbra (PEN) Spring a Surprise this Earnings Season?
Feb-21-17 08:46AM  Patterson Companies (PDCO) Q3 Earnings: What's in Store?
Feb-20-17 07:52AM  Forget Alexion, Buy these 4 Biotech Stocks Instead
05:15AM  Medtronic (MDT) Q3 Earnings: Disappointment in the Cards?
Feb-17-17 05:02PM  Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refractory Metastatic Urothelial Carcinoma and Other Genitourinary Tumors Business Wire
02:30PM  Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?
09:30AM  Easier Regulatory Environment Could Send Biotech Industry Skyrocketing in 2017: Today's Reports on Neuralstem and Exelixis Accesswire
Feb-15-17 02:44PM  Two Great Stock Ideas in the IBB Biotech ETF at Investopedia
Feb-14-17 09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics
Feb-13-17 05:17PM  Better Buy: Exelixis, Inc. vs. Bristol-Myers Squibb at Motley Fool
09:14AM  Forget Gilead, Buy These 5 Biotech Stocks Instead
Feb-10-17 09:42AM  Can Allscripts (MDRX) Surprise Investors in Q4 Earnings?
09:30AM  Zacks.com featured highlights: Exelixis, RPC, Unit and Fortress Transportation and Infrastructure Investors
04:10AM  Exelixis (EXEL) Shares March Higher, Can It Continue?
Feb-09-17 12:37PM  Harry Boxers stocks to watch: biotechnology and technology at MarketWatch
10:15AM  Ecolab (ECL): What's in the Cards this Earnings Season?
09:27AM  Buy 4 Stocks Riding High on Superb Earnings Acceleration
07:39AM  5 Drug Stocks Poised to Beat Earnings Estimates in Q4
Feb-08-17 04:53PM  3 Scorching Hot Biotech Stocks -- Are They Buys? at Motley Fool +5.06%
01:49PM  Four Biotech Stocks Breaking Out at Forbes
10:10AM  DENTSPLY (XRAY) Q4 Earnings: Is Disappointment in Store?
09:30AM  The Zacks Analyst Blog Highlights: Celgene, Exelixis, Ligand Pharmaceuticals and RedHill Biopharma
09:30AM  The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals
Feb-07-17 04:05PM  Exelixis to Present at the Leerink Partners Global Healthcare Conference on February 15 Business Wire
03:26PM  5 Great Biotech Stocks to Buy Now
07:41AM  4 Drug Stocks that are Broker Favorites
Feb-03-17 11:17AM  Hopes for Tax Reform, Less Regulation Lift Indices +8.40%
Feb-02-17 04:05PM  Exelixis to Release Fourth Quarter and Full Year 2016 Financial Results on Monday, February 27, 2017 Business Wire
07:37AM  2 Big Reasons Exelixis, Inc. Soared 22% in January at Motley Fool
Feb-01-17 08:15AM  Blog Coverage Exelixis Partners with Takeda to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan Accesswire
Jan-31-17 04:05PM  Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
11:24AM  Exelixis, Takeda Sign Japanese Cancer Drug Deal at Investopedia
07:00AM  Exelixis Inks Partnership with Takeda for Cabometyx in Japan
Jan-30-17 06:00PM  Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan Business Wire
07:27AM  3 Mid-Cap Biotech Stocks to Buy in February at Motley Fool
Jan-27-17 09:45AM  Biotech M&A Activity Expected to Rise in 2017: Latest Reports on Exelixis and Vertex Pharmaceuticals Accesswire
Jan-23-17 05:27PM  Better Buy: Exelixis, Inc. vs. Novartis at Motley Fool
Jan-11-17 10:49AM  Exelixis, Inc. Value Analysis (NASDAQ:EXEL) : January 11, 2017
Jan-10-17 12:21PM  After ARIAD's Acquisition, These 3 Cancer Drug Stocks Could Be Next at Motley Fool +7.57%
09:27AM  4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal
09:20AM  Genentech Withdraws Cost Claims Against Exelixis at Investopedia
07:23AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : January 10, 2017
Jan-09-17 04:14PM  Why Exelixis, Inc. Stock Zoomed Higher Today at Motley Fool +14.75%
07:25AM  3 Stocks Expected to More Than Double Their Earnings in 2017 at Motley Fool
05:13AM  Update on Dispute between Exelixis and Genentech, a Member of the Roche Group Business Wire
Jan-05-17 09:43AM  The 4 Building Blocks That Pushed Exelixis, Inc. Higher by 164% in 2016 at Motley Fool
Jan-04-17 09:15AM  Biotech Stocks to Watch in 2017 ACADIA Pharmaceuticals and Exelixis Accesswire
08:49AM  How calls are looking for Exelixis rally
07:24AM  Is It Too Late to Buy Exelixis Stock? at Motley Fool
Jan-03-17 06:07PM  Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Business Wire
02:04PM  ETFs with exposure to Exelixis, Inc. : January 3, 2017
10:08AM  Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year at Motley Fool
Dec-30-16 04:22PM  Biotech Stocks: What to Watch in 2017 at Motley Fool
08:25AM  Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : December 30, 2016
Dec-29-16 05:29PM  4 Biotech Stocks with Bright Prospects in 2017
Dec-28-16 07:23AM  The 3 Biggest Risks for Pfizer in 2017 at Motley Fool
Dec-24-16 02:52PM  Better Buy: Celldex Therapeutics, Inc. vs. Exelixis at Motley Fool
Dec-23-16 09:30AM  The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen
Dec-22-16 06:18PM  Exelixis, Ipsen Amend Exclusive Agreement for Cabometyx -8.46%
09:28AM  4 Biotech Stocks that More than Doubled in 2016
Dec-21-16 06:06AM  EXELIXIS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
01:22AM  Exelixis Stock Is Up 203% in 2016 -- Is There Still More Upside Ahead? at Motley Fool
01:00AM  Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada Business Wire
01:00AM  Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada Business Wire
Dec-19-16 02:06PM  Forget Marijuana Stocks: Buy These 3 Biotech Stocks Instead at Motley Fool
09:28AM  7 Top Stocks We're Excited About Headed Into 2017 at Motley Fool
09:10AM  The Best Biopharma CEOs of 2016 Are...
Dec-14-16 01:02PM  ETFs with exposure to Exelixis, Inc. : December 14, 2016
09:30AM  The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis
Dec-13-16 01:19PM  Here's Why Trump's Pledge to Lower Drug Prices Is All Bark and No Bite at Motley Fool
08:09AM  3 Great Stocks to Beat the Biotech Blues
Dec-12-16 09:03AM  2 Companies I Wish I'd Bought in 2016 at Motley Fool
Dec-07-16 08:38AM  Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy? -8.99%
08:00AM  Exelixis Announces Leadership Hires in Public Affairs and Business Development to Support Growth of Company and Pipeline Business Wire
Dec-05-16 06:11PM  This Dynamic Duo of Catalysts Sent Exelixis, Inc. Higher by 60% in November at Motley Fool
03:15AM  Hedge Funds Arent Crazy About John Bean Technologies Corp (JBT) Anymore at Insider Monkey
Dec-02-16 01:03PM  Why Exelixis Was a Top Stock in 2016 So Far at Motley Fool +5.15%
09:21AM  3 Biotech Stocks to Buy in December at Motley Fool
Dec-01-16 04:20PM  5 Top Performing Biotechnology Stocks of November
11:08AM  Exelixis (EXEL): Strong Industry, Solid Earnings Estimate Revisions
Nov-30-16 07:43PM  5 Stocks Up 100% or More This Year at Motley Fool
05:36PM  Is Wright Medical Group Inc (WMGI) a Good Stock for Your Portfolio? at Insider Monkey
04:41PM  What's Pfizer's Excuse for Not Buying Exelixis? at Motley Fool
04:15PM  Exelixis to Present at the BMO Prescription for Success Healthcare Conference on December 14 Business Wire
10:40AM  Hedge Funds Are Buying RealPage, Inc. (RP) at Insider Monkey
10:02AM  The 5 Best Biotech Stocks of 2016 at Motley Fool
09:46AM  Should You Buy Exelixis, Inc. (EXEL)? at Insider Monkey
Nov-29-16 01:52PM  Shark Bites: Eager Buyers Pounce on Pullback
Nov-28-16 07:32PM  3 Healthcare Stocks Investors Have Been Thankful for This Year at Motley Fool
Nov-24-16 05:48PM  The Healthcare Gurus at Baker Bros. Advisors Were Buying These Stocks in Q3 at Insider Monkey
Nov-23-16 09:30AM  4 stocks to watch at MarketWatch
Nov-22-16 05:09PM  EXELIXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -5.36%
01:49PM  How to Be a Smarter Biotech Investor
08:54AM  Sanofi (SNY) Soliqua Approved for Type 2 Diabetes in Adults
Nov-21-16 04:17PM  Exelixis to Present at the Piper Jaffray 28th Annual Healthcare Conference on November 29 Business Wire
Nov-18-16 04:40PM  Is Exelixis the Best Small-Cap Biotech Stock? at Motley Fool
09:30AM  New Oriental Education & Technology Group, BJ's Restaurants, ARIAD Pharmaceuticals, Incyte and Exelixis highlighted as Zacks Bull and Bear of the Day
08:48AM  Endo Reports Positive Cellulite Treatment Data on Xiaflex
Nov-17-16 09:29AM  3 Things Exelixis Must Do to Survive and Thrive in 2017 at Motley Fool
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. It focuses on advancing cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. The company has received regulatory approval for two separate formulations of cabozantinib for the treatment of certain forms of kidney and thyroid cancer and marketed as CABOMETYX tablets in the United States and COMETRIQ capsules in the United States and European Union respectively. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in the United States and European Union; and is being evaluated for further potential indications by Roche and Genentech under collaboration with Exelixis. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Option Exercise6.9270,000484,300143,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Sale18.6570,0001,305,50073,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Option Exercise5.7470,000401,800143,600Jan 05 08:25 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Sale14.6570,0001,025,63673,600Jan 05 08:25 PM
FELDBAUM CARL BDirectorDec 16Option Exercise10.4125,000260,25073,721Dec 16 07:29 PM
FELDBAUM CARL BDirectorDec 16Sale17.0325,000425,75048,721Dec 16 07:29 PM
Garber Alan MDirectorDec 09Option Exercise10.5310,000105,30069,161Dec 09 08:02 PM
Garber Alan MDirectorDec 09Sale16.907,832132,36161,329Dec 09 08:02 PM
SCANGOS GEORGE ADirectorDec 07Option Exercise8.993563,2001,463,824Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 07Sale17.901763,1501,463,648Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 05Option Exercise8.99357,9763,218,2041,668,186Dec 07 07:03 PM
SCANGOS GEORGE ADirectorDec 05Sale17.81204,7183,646,0281,463,468Dec 07 07:03 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Option Exercise8.9922,000197,780180,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Option Exercise5.2770,000368,800143,600Dec 02 07:14 PM
Lamb PeterEVP, Scientific Strategy & CSODec 01Sale16.6670,0001,166,20073,600Dec 02 07:14 PM
Schwab GiselaPres Prod Dev & Med Aff & CMODec 01Sale16.7322,000368,060158,053Dec 02 07:13 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Option Exercise5.1770,000362,000143,600Nov 14 07:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Option Exercise8.9922,000197,780180,053Nov 14 07:36 PM
MORRISSEY MICHAELPresident and CEONov 09Option Exercise8.99200,0001,798,000260,000Nov 14 07:37 PM
MORRISSEY MICHAELPresident and CEONov 09Sale15.00200,0003,000,00060,000Nov 14 07:37 PM
Schwab GiselaPres Prod Dev & Med Aff & CMONov 09Sale15.0022,000330,000158,053Nov 14 07:36 PM
Lamb PeterEVP, Scientific Strategy & CSONov 09Sale13.1570,000920,50073,600Nov 14 07:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 31Option Exercise9.73132,6621,290,801267,596Sep 02 04:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 31Sale10.98131,1551,440,082136,441Sep 02 04:34 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 04Option Exercise9.7342,338411,949174,354Aug 05 07:29 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOAug 04Sale11.0042,338465,718132,016Aug 05 07:29 PM
Hessekiel JeffreyEVP and General CounselJun 01Option Exercise1.70200,000340,000230,367Jun 02 06:37 PM
WILLSEY LANCEDirectorMay 11Buy4.9520,00099,000568,273May 11 05:23 PM
WILLSEY LANCEDirectorMay 09Buy4.9740,000198,900548,273May 11 05:23 PM
NILE Blue Nile, Inc. daily Stock Chart
NILE [NASD]
Blue Nile, Inc.
Index- P/E49.89 EPS (ttm)0.82 Insider Own2.70% Shs Outstand11.73M Perf Week-0.02%
Market Cap477.53M Forward P/E43.77 EPS next Y0.93 Insider Trans-0.06% Shs Float10.98M Perf Month0.15%
Income9.50M PEG2.49 EPS next Q0.46 Inst Own87.60% Short Float2.77% Perf Quarter0.79%
Sales471.90M P/S1.01 EPS this Y12.40% Inst Trans-9.78% Short Ratio1.85 Perf Half Y32.00%
Book/sh1.60 P/B25.44 EPS next Y5.68% ROA8.10% Target Price28.00 Perf Year56.10%
Cash/sh3.46 P/C11.76 EPS next 5Y20.00% ROE59.30% 52W Range24.04 - 41.39 Perf YTD0.20%
Dividend- P/FCF91.83 EPS past 5Y-0.90% ROI55.10% 52W High-1.64% Beta0.12
Dividend %- Quick Ratio0.50 Sales past 5Y7.60% Gross Margin19.60% 52W Low69.34% ATR0.04
Employees335 Current Ratio1.00 Sales Q/Q-4.40% Oper. Margin3.00% RSI (14)55.45 Volatility0.08% 0.10%
OptionableYes Debt/Eq0.02 EPS Q/Q-35.40% Profit Margin2.00% Rel Volume0.49 Prev Close40.71
ShortableNo LT Debt/Eq0.02 EarningsFeb 15 BMO Payout0.00% Avg Volume164.71K Price40.71
Recom3.00 SMA20-0.01% SMA500.18% SMA20019.24% Volume0 Change0.00%
Feb-12-16Reiterated RBC Capital Mkts Sector Perform $39 → $24
Feb-11-16Downgrade BofA/Merrill Buy → Underperform
Nov-06-15Reiterated RBC Capital Mkts Sector Perform $33 → $39
Aug-10-15Reiterated RBC Capital Mkts Sector Perform $30 → $33
May-11-15Reiterated RBC Capital Mkts Sector Perform $28 → $30
Feb-11-15Reiterated RBC Capital Mkts Sector Perform $35 → $28
Feb-11-15Reiterated Deutsche Bank Buy $40 → $32
Feb-11-15Reiterated B. Riley & Co. Buy $48 → $42
Aug-06-14Reiterated RBC Capital Mkts Sector Perform $37 → $26
May-02-14Reiterated Deutsche Bank Buy $43 → $40
Sep-26-13Initiated B. Riley & Co. Buy $49
May-23-13Downgrade RBC Capital Mkts Outperform → Sector Perform $36 → $36
May-03-13Reiterated The Benchmark Company Hold $28 → $32
Feb-13-13Reiterated Deutsche Bank Buy $53 → $49
Oct-04-12Initiated Capstone Investments Buy $45
May-09-12Reiterated The Benchmark Company Hold $22 → $32
Feb-16-12Reiterated RBC Capital Mkts Sector Perform $44 → $40
May-06-11Reiterated The Benchmark Company Hold $44 → $40
Jan-10-11Upgrade The Benchmark Company Sell → Hold $35 → $46
Oct-26-10Downgrade MKM Partners Buy → Neutral $57 → $42
Feb-21-17 07:27AM  Blue Nile, Inc. breached its 50 day moving average in a Bullish Manner : NILE-US : February 21, 2017
Feb-20-17 04:27PM  Blue Nile, Inc.: Leads amongst peers with strong fundamentals
Feb-17-17 05:41PM  Sucampo Pharmaceuticals Set to Join S&P SmallCap 600 PR Newswire
05:12PM  [$$] Deal Close Announcements: Feb. 13-17 at The Wall Street Journal
03:50PM  Blue Nile delists from the Nasdaq exchange Tuesday after closing $500M sale at bizjournals.com
10:51AM  BLUE NILE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligati
10:23AM  Investor Group Completes Acquisition of Blue Nile GlobeNewswire
Feb-15-17 07:10AM  BLUE NILE INC Files SEC form 8-K, Regulation FD Disclosure
Feb-09-17 08:20PM  Pay's up and down for the leaders of the Seattle area's national retailers at bizjournals.com
Feb-06-17 08:15AM  Blog Coverage Shareholders of Online Jeweler Blue Nile Approve the Takeover by Bain Capital Accesswire
Feb-02-17 07:20PM  Blue Nile shareholders agree to $500M acquisition at bizjournals.com
05:04PM  BLUE NILE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jan-25-17 02:40PM  Shareholder files lawsuit to block Blue Nile's $500M sale at bizjournals.com
Jan-24-17 06:08AM  BLUE NILE INC Files SEC form 8-K, Other Events
Jan-19-17 10:00AM  Mondiamo partners with Blue Nile to revolutionize the way consumers sell their diamond jewelry GlobeNewswire
Jan-12-17 08:15AM  Blog Coverage Signet's Sales Declined in the Holiday Season; Cuts Same-Store Sales Outlook Accesswire
Dec-28-16 04:20PM  Blue Nile was shopping for suitors two years prior to announced sale at bizjournals.com
Dec-16-16 05:14PM  BLUE NILE INC Files SEC form 8-K, Other Events
06:02AM  How CU Bancorp (CUNB) Stacks Up Against Its Peers at Insider Monkey
Dec-14-16 12:14AM  Is Blue Nile Inc (NILE) Right for Your Portfolio? at Insider Monkey
Dec-07-16 09:04AM  BLUE NILE INC Files SEC form 8-K, Other Events
Dec-05-16 03:06PM  Why Shares of Tiffany & Co. Popped 12% in November at Motley Fool
Dec-02-16 05:42PM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of The Board of Directors of Blue Nile - NILE PR Newswire
Dec-01-16 11:45AM  Lifshitz & Miller Law Firm Announces Investigation of Alexion Pharmaceuticals, Inc., Blue Nile, Inc., Hill International, Inc., InfuSystem Holdings Inc., Rent-A-Center, Inc., Treehouse Foods, Inc. and Viking Investments Group, Inc. PR Newswire
09:03AM  BLUE NILE INC Files SEC form 8-K, Other Events
Nov-28-16 07:12PM  Blue Nile CEO Sees Changing Shoppers, Smarter Consumers at Motley Fool
01:54PM  Blue Nile CEO: Webrooms resonating well with Millenials
Nov-25-16 10:00AM  Blue Nile, Inc. (Nasdaq: NILE) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Nov-23-16 11:38AM  LPC: Black Friday could shine light on troubled US retail loans Reuters
Nov-22-16 10:30AM  Blue Nile Opens Webroom in Seattle Area GlobeNewswire
10:27AM  Blue Nile, Inc. :NILE-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016
10:13AM  Signet: A Diamond In The Rough Or A Hunk Of Coal? at Barrons.com
Nov-17-16 09:05PM  SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of Blue Nile, Inc. -NILE PR Newswire
01:04PM  BLUE NILE INC Financials
Nov-16-16 03:07PM  Blue Nile, Rent the Runway bet on shoppers wanting stores
Nov-14-16 02:14PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Blue Nile Inc. to a Consortium for $40.75 Per Share is Fair to Shareholders -- NILE PR Newswire
Nov-11-16 11:15PM  INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Blue Nile Inc. And Encourages Shareholders To Contact The Firm For Additional Information Business Wire
Nov-09-16 05:22PM  BLUE NILE INC Files SEC form 10-Q, Quarterly Report
03:03PM  INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Blue Nile Inc. to a Consortium for $40.75 Per Share is Fair to Shareholders Business Wire
02:57PM  BLUE NILE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blue Nile, Inc. PR Newswire
01:06PM  ETFs with exposure to Blue Nile, Inc. : November 9, 2016
12:55PM  Blue Nile, Inc. Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Merger with Bain Capital Private Equity and Bow Street LLC Business Wire
Nov-08-16 05:08PM  Harwood Feffer LLP Announces Investigation of Blue Nile, Inc. PR Newswire
03:43PM  Blue Nile, Inc.: Leads amongst peers with strong fundamentals
02:32PM  SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Blue Nile Inc. And Encourages Investors To Contact The Firm For Additional Information Business Wire
11:07AM  Ryan & Maniskas, LLP Announces Investigation of Blue Nile Inc. PR Newswire
08:15AM  Blog Coverage Blue Nile to be Taken Private in a $500 Million Deal Accesswire
08:14AM  Blue Nile, Inc. breached its 50 day moving average in a Bullish Manner : NILE-US : November 8, 2016
Nov-07-16 05:20PM  Happy Couples Don't Buy Diamonds Online the Way They Used To +33.90%
04:52PM  What Happened in the Stock Market Today at Motley Fool
03:54PM  Blue Nile Sold to a PE Group at a 34% Premium at Investopedia
02:55PM  BLUE NILE, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Business Wire
01:41PM  Blue Nile Inc. to Go Private at Motley Fool
01:30PM  Online jeweler Blue Nile sold to private equity firms for $500M; stock soars at bizjournals.com
12:47PM  PE Steps Up To Buy Online Engagement Ring Retailer Blue Nile
12:43PM  Blue Nile Stock Explodes On Buyout -- Time for Tiffany (TIF) to Sell?
12:06PM  Why Blue Nile Inc. Stock Skyrocketed 34% Today at Motley Fool
10:30AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Blue Nile Inc. to a Consortium for $40.75 Per Share is Fair to Shareholders -- NILE Accesswire
08:55AM  BLUE NILE (NILE) ALERT: Johnson & Weaver, LLP Launches an Investigation into the Fairness of Price and Process in Proposed Sale of Blue Nile, Inc.; Are Shareholders Receiving a Fair Price? PR Newswire
08:23AM  [$$] Blue Nile to Be Taken Private at The Wall Street Journal
08:21AM  Online jeweler Blue Nile agrees to be taken private for $500 mln Reuters
07:43AM  Blue Nile to be bought out by Bain for $500 million, a 34% premium for shareholders at MarketWatch
07:42AM  Jeweler Blue Nile agrees to be taken private for $500 mln
07:40AM  Blue Nile posts 3Q profit
07:36AM  BLUE NILE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:32AM  Blue Nile Announces Third Quarter 2016 Financial Results GlobeNewswire
07:30AM  Blue Nile Enters Into Definitive Agreement to be Acquired by Bain Capital Private Equity and Bow Street LLC for Approximately $500 Million GlobeNewswire
07:07AM  Q3 2016 Blue Nile Inc Earnings Release - Before Market Open
Oct-28-16 04:20PM  Blue Nile CEO is 9 years cancer-free and the top-fundraiser for Fred Hutch's Obliteride at bizjournals.com
Oct-27-16 08:36AM  Blue Nile, Inc. breached its 50 day moving average in a Bearish Manner : NILE-US : October 27, 2016
Oct-24-16 05:00PM  Blue Nile Schedules Third Quarter 2016 Earnings Release and Conference Call GlobeNewswire
Oct-20-16 09:48AM  ETFs with exposure to Blue Nile, Inc. : October 20, 2016
Sep-14-16 12:00AM  Reasons To Sell a Stock #2: Core Business Issues at Motley Fool
Sep-10-16 12:08AM  Forget the Safari: Africas Most Intriguing New Destination at The Wall Street Journal
Sep-07-16 06:51PM  Why Blue Nile Inc Stock Soared 18% in August at Motley Fool
Sep-06-16 02:35PM  Online jeweler Blue Nile brings its brick-and-mortar strategy to Bellevue at bizjournals.com
11:00AM  Blue Nile Brings Retail Reimagined Concept to Seattle GlobeNewswire
Sep-04-16 03:06PM  4 Reasons to Sell a Stock at Motley Fool
Sep-02-16 11:42AM  Blue Nile Opens First West Coast Webroom GlobeNewswire
Aug-25-16 10:24AM  ETFs with exposure to Blue Nile, Inc. : August 25, 2016
Aug-12-16 02:36PM  ETFs with exposure to Blue Nile, Inc. : August 12, 2016
09:13AM  Is The Sparkle Coming Off of Jewelry Stocks? at Insider Monkey
Aug-11-16 11:47AM  Blue Nile, Inc. :NILE-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016
Aug-09-16 05:07PM  BLUE NILE INC Files SEC form 10-Q, Quarterly Report
Aug-08-16 04:21PM  Blue Nile posts 2Q profit
04:14PM  BLUE NILE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Blue Nile Announces Second Quarter 2016 Financial Results GlobeNewswire
07:07AM  Q2 2016 Blue Nile Inc Earnings Release - Before Market Open
Aug-04-16 05:20PM  BLUE NILE INC Files SEC form 8-K/A, Change in Directors or Principal Officers
Jul-25-16 05:00PM  Blue Nile Schedules Second Quarter 2016 Earnings Release and Conference Call GlobeNewswire
Jul-21-16 05:30PM  Blue Nile Announces Changes on Board of Directors GlobeNewswire
05:03PM  BLUE NILE INC Files SEC form 8-K, Change in Directors or Principal Officers
Jul-20-16 09:30AM  The Zacks Analyst Blog Highlights: eBay, Amazon, Expedia, Autobytel and Blue Nile
Jul-19-16 12:20PM  What's Ahead For These eCommerce Stocks In Q2 Earnings?
Jul-18-16 09:15AM  Is Tiffany & Co. Stock a Buy? at Motley Fool
Jun-30-16 03:21PM  Blue Nile, Inc. Value Analysis (NASDAQ:NILE) : June 30, 2016
Jun-29-16 05:23PM  Why Brexit could bring the IPO market to a screeching halt
08:07AM  Blue Nile, Inc. breached its 50 day moving average in a Bullish Manner : NILE-US : June 29, 2016
Jun-22-16 06:09PM  What's the Best Internet Stock for the Summer?
Jun-20-16 05:59AM  What Awaits Constellation Brands (STZ) in Q1 Earnings?
Blue Nile, Inc. operates as an online retailer of diamonds and fine jewelry worldwide. It offers engagement products, such as gold or platinum engagement rings with a diamond center stone and loose diamonds; and non-engagement products, including rings, wedding bands, earrings, necklaces, pendants, bracelets, gifts, and accessories containing precious metals, diamonds, gemstones, or pearls. Blue Nile, Inc. sells its products through its Website, bluenile.com. The company was formerly known as Internet Diamonds, Inc. and changed its name to Blue Nile, Inc. in November 1999. Blue Nile, Inc. was founded in 1999 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sainsbury JonChief Revenue OfficerSep 02Sale35.501906,74530,487Sep 07 07:23 PM
Sainsbury JonChief Revenue OfficerJul 13Sale30.001003,00030,918Jul 15 07:10 PM
POTTER MICHAEL JDirectorMay 11Buy25.554,000102,18716,504May 13 06:24 PM